Contribution of¹⁸Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma

Article type: Research Article

Authors: Kanmaz, Zehra Dilek^{a; *} | Aras, Gülfidan^a | Tuncay, Esin^a | Bahadır, Ayşe^a | Kocatürk, Celalettin^a | Yaşar, Zehra Asuk^b | Öz, Büge^c | Özkurt, Canan Ünlü^c | Gündoğan, Cihan^d | Çermik, Tevfik Fikret^d

Affiliations: [a] Yedikule Chest Diseases Research and Training Hospital, Istanbul, Turkey | [b] Abant Izzet Baysal University School of Medicine, Istanbul, Turkey | [c] Cerrahpasa Medical Faculty, Pathology Department Istanbul University, Istanbul, Turkey | [d] Department of Nuclear Medicine, Istanbul Training and Research Hospital, Istanbul, Turkey

Correspondence: [*] Corresponding author: Zehra Dilek Kanmaz, Yedikule Chest Diseases Research and Training Hospital, Istanbul, Turkey. Tel.: +90 5357800706; E-mail:dlkkanmaz@yahoo.com

Abstract: AIM: The aim of this study is to evaluate the diagnostic value of PET-CT scan for the prediction of EGFR mutation status and the contribution of TTF-1 expression to PET-CT scan. METHODS: We retrospectively studied 218 cases with a diagnosis of pulmonary adenocarcinoma between 2012-2014 which underwent EGFR analysis, TTF-1 and PET-CT before treatment. RESULTS: The EGFR mutation was present in 28.9% (n= 63) of cases. TTF-1 positivity was 66.9% (n= 105). Standardized uptake value (SUV max) was 16.7 ± 6.8 in EGFR mutant type, 13.8 ± 7.6 in cases having no EGFR mutations. According to our evaluations, high SUVmax is positively correlated with EGFR mutation status. TTF-1 expression in multivariate analysis strengthens the accuracy of detecting an EGFR mutation. CONCLUSION: PET-CT FDG uptake may, together with TTF-1 expression, help diagnosis in lung adenocarcinoma cases when evaluating for EGFR mutation status.

Keywords: Lung cancer, EGFR, TTF-1

DOI: 10.3233/CBM-160588

Journal: Cancer Biomarkers, vol. 16, no. 3, pp. 489-498, 2016